{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:00:23Z","timestamp":1792792823653,"version":"4.5.0"},"reference-count":233,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"Italian Ministry of Health (Ricerca Corrente 2023), Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan","id":[{"id":"https:\/\/ror.org\/0053ctp29","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2024,5,3]]},"DOI":"10.1080\/1744666x.2023.2298356","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T03:11:16Z","timestamp":1703214676000},"page":"525-545","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":52,"title":["Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm"],"prefix":"10.1080","volume":"20","author":[{"given":"Carlo Alberto","family":"Maronese","sequence":"first","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Moltrasio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Genovese","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0759"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.09.008"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1677"},{"issue":"1","key":"e_1_3_4_8_1","first-page":"40","article-title":"Hidradenitis suppurativa: an up-to-date review of clinical features, pathogenesis and therapeutic approaches","volume":"30","author":"Moussa A","year":"2022","unstructured":"Moussa A, Willems A, Sinclair RD. Hidradenitis suppurativa: an up-to-date review of clinical features, pathogenesis and therapeutic approaches. Wound Pract Res. 2022;30(1):40\u201349.","journal-title":"Wound Pract Res"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14038"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1301"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14464"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2020.10.016"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094874"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.02.003"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02965"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10082039"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2217"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2227"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01518-3"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000610"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI131180"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1007705"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139930"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac048"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.10.034"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18163"},{"key":"e_1_3_4_28_1","unstructured":"Novartis [Internet]. East Hanover (NJ): news. FDA approves Novartis Cosentyx\u00ae as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade. 2023 Oct 31 [cited 2023 Nov 13]. Available from: https:\/\/www.novartis.com\/us-en\/news\/media-releases\/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16115"},{"key":"e_1_3_4_30_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A randomized double-blind placebo controlled multiple dose study to evaluate the clinical efficacy safety tolerability dose relation pharmacokinetics and pharmacodynamics of CJM112 in moderate to severe chronic hidradenitis suppurativa patients. 2022 Jul 13 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02421172"},{"key":"e_1_3_4_31_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Hidradenitis suppurativa phase 2b pivotal study of Izokibep. 2023 Nov 2 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05355805"},{"key":"e_1_3_4_32_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Hidradenitis suppurativa study of Izokibep. 2023 Nov 7 [cited 2023 Nov 13]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05905783"},{"key":"e_1_3_4_33_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Evaluation of sonelokimab for the treatment of patients with active moderate to severe hidradenitis suppurativa. 2023 Oct 10 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05322473"},{"key":"e_1_3_4_34_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A phase 3 open-label parallel group multicenter extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa. 2023 Oct 27 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04901195"},{"key":"e_1_3_4_35_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A study to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (BE HEARD I). 2023 Apr 7 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04242446"},{"key":"e_1_3_4_36_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A phase 3 randomized double-blind placebo-controlled multicenter study evaluating the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa. 2023 Oct 17 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04242498"},{"key":"e_1_3_4_37_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A multicenter double-blind randomized withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy safety and tolerability in subjects with moderate to severe hidradenitis suppurativa. 2023 Oct 27 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04179175"},{"key":"e_1_3_4_38_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A randomized double-blind placebo-controlled multicenter phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa. 2021 Apr 8 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03487276"},{"key":"e_1_3_4_39_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Safety and efficacy study of BDB-001 injection in patients with moderate to severe hidradenitis suppurativa (HS). 2023 Jun 27 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05103423"},{"key":"e_1_3_4_40_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Efficacy and safety study of BDB-001 injection in patients with moderate to severe hidradenitis suppurativa (HS). 2023 Aug 29 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05093855"},{"key":"e_1_3_4_41_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa. 2023 Sep 13 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04762277"},{"key":"e_1_3_4_42_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Lunsayil 1: a study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa. 2023 Nov 3 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05819398"},{"key":"e_1_3_4_43_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A study investigating long-term treatment with spesolimab in people with a skin disease called hidradenitis suppurativa who completed a previous clinical trial. 2023 Aug 31 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04876391"},{"key":"e_1_3_4_44_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A study to evaluate the efficacy safety and tolerability of bermekimab in patients with hidradenitis suppurativa. 2023 Jul 27 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04019041"},{"key":"e_1_3_4_45_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A study of bermekimab for the treatment of participants with moderate to severe hidradenitis suppurativa (LYRA). 2023 Nov 13 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04988308"},{"key":"e_1_3_4_46_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A study to assess disease activity and safety of subcutaneous lutikizumab (ABT-981) in adult participants with moderate to severe hidradenitis suppurativa who have failed anti-tumor necrosis factor (TNF) therapy. 2023 Sep 13 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05139602"},{"key":"e_1_3_4_47_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativa (HS OBTAIN). 2023 Oct 30 [cited 2023 Nov 13]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05849922"},{"key":"e_1_3_4_48_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Efficacy and safety of infliximab biosimilar in treatment of resistant hidradenitis suppurativa. 2022 Dec 23 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05663268"},{"key":"e_1_3_4_49_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A study of LY3041658 in adults with hidradenitis suppurativa. 2023 Apr 28 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04493502"},{"key":"e_1_3_4_50_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis. 2023 May 26 [cited 2023 Nov 13]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03972280"},{"key":"e_1_3_4_51_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Study of efficacy and safety of investigational treatments in patients with moderate to severe hidradenitis suppurativa. 2023 Nov 8 [cited 2023 Nov 13]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03827798"},{"key":"e_1_3_4_52_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Trial to determine the immunomodulatory activity of PTM-001 in patients with hidradenitis suppurativa. 2022 Oct 26 [cited 2023 Nov 13]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05020730"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S402453"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010044"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14633"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.059"},{"issue":"2","key":"e_1_3_4_57_1","first-page":"455","article-title":"Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review","volume":"10","author":"Ruggiero A","year":"2022","unstructured":"Ruggiero A, Martora F, Picone V, et al. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review. Biomed. 2022;10(2):455.","journal-title":"Biomed"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0749"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10254.x"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17641"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17598"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17551"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026190"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S391356"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16835"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18983"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.603281"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.23736\/S2784-8671.21.07049-3"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1159\/000512617"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.064"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1914309"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1159\/000531558"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.06.152"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00579-z"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac007"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20097"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14448"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.4805"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503606"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20525"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6868"},{"issue":"10","key":"e_1_3_4_83_1","first-page":"1518","article-title":"Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response-data from the German HS Registry HSBest","volume":"12","author":"Kirsten N","year":"2022","unstructured":"Kirsten N, Ohm F, Gehrdau K, et al. Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response-data from the German HS Registry HSBest. Life (Basel). 2022;12(10):1518.","journal-title":"Life (Basel)"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11041007"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102522"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18801"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15691"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2011.571657"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.683767"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.022"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.0220"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad224"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15286"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15782"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15266"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.04.026"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.72"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169479"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad225"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad184"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5377"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.044"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13292"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13528"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1159\/000343221"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.2392"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3903"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221801"},{"issue":"9","key":"e_1_3_4_109_1","first-page":"36","article-title":"Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa","volume":"10","author":"Sun NZ","year":"2017","unstructured":"Sun NZ, Ro T, Jolly P, et al. Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa. J Clin Aesthet Dermatol. 2017;10(9):36\u201338.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15743"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_147_16"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15002"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.10.030"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.10.024"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14333"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08360-9"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.06.019"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00022-3"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17822"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.007"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19478"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2905"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754211035667"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1159\/000521860"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1974395"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14417"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3813"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13232"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16605"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17178"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18685"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00906-2"},{"key":"e_1_3_4_133_1","volume-title":"Late breaking platform presented at: American Academy of Dermatology (AAD) Annual Meeting","author":"Kimball AB","year":"2023","unstructured":"Kimball AB, Zouboulis CC, Sayed C. Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: 48-week efficacy and safety from BE HEARD I & II, two phase 3, randomized, double-blind, placebo controlled, multicenter studies. Late breaking platform presented at: American Academy of Dermatology (AAD) Annual Meeting; 2023 March 17\u201321; New Orleans, LA, USA."},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad229"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18556"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad130"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14619"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13756"},{"issue":"6","key":"e_1_3_4_139_1","first-page":"788","article-title":"Ixekizumab in hidradenitis suppurativa in a psoriatic patient","volume":"155","author":"Odorici G","year":"2020","unstructured":"Odorici G, Pellacani G, Conti A. Ixekizumab in hidradenitis suppurativa in a psoriatic patient. G Ital Dermatol Venereol. 2020;155(6):788\u2013789.","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.12.036"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1755008"},{"issue":"3","key":"e_1_3_4_142_1","first-page":"319","article-title":"Ustekinumab in the management of hidradenitis suppurativa: a retrospective study","volume":"21","author":"Hollywood A","year":"2022","unstructured":"Hollywood A, Murray G, Fleming S, et al. Ustekinumab in the management of hidradenitis suppurativa: a retrospective study. J Drugs Dermatol. 2022;21(3):319\u2013320.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21066"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1776208"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14338"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1159\/000501075"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14054"},{"issue":"9","key":"e_1_3_4_148_1","doi-asserted-by":"crossref","DOI":"10.5070\/D3259045519","article-title":"Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab","volume":"25","author":"Cline A","year":"2019","unstructured":"Cline A, Pichardo RO. Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab. Dermatol Online J. 2019;25(9):13030\/qt0hw2w4nr.","journal-title":"Dermatol Online J"},{"key":"e_1_3_4_149_1","unstructured":"ClinicalTrials.gov ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A study of combination therapy with guselkumab and golimumab in participants with moderately to severely active crohn\u2019s disease (DUET-CD). 2023 Nov 8 [cited Nov 13]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05242471"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00427-7"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00699-8"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01931-3"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14338"},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15558"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15368"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.017"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13456"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14930"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15116"},{"key":"e_1_3_4_160_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19716"},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.2926"},{"key":"e_1_3_4_162_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15704"},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13285"},{"key":"e_1_3_4_164_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13559"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19252"},{"key":"e_1_3_4_166_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00913-3"},{"key":"e_1_3_4_167_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad010"},{"issue":"23","key":"e_1_3_4_168_1","first-page":"00604","article-title":"The effectiveness of guselkumab in patients with hidradenitis suppurativa under clinical practice conditions: a Spanish multicentre retrospective study","volume":"0001","author":"Rivera-D\u00edaz R","year":"2023","unstructured":"Rivera-D\u00edaz R, Pozo T, Alfageme F, et al. The effectiveness of guselkumab in patients with hidradenitis suppurativa under clinical practice conditions: a Spanish multicentre retrospective study. Actas Dermosifiliogr. 2023;S0001\u20137310(23):00604\u2013X.","journal-title":"Actas Dermosifiliogr"},{"key":"e_1_3_4_169_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.5278"},{"key":"e_1_3_4_170_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad215"},{"key":"e_1_3_4_171_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14789"},{"key":"e_1_3_4_172_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953674"},{"key":"e_1_3_4_173_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18877"},{"key":"e_1_3_4_174_1","unstructured":"inflaRX [Internet]. Jena (Deu): press release. InflaRx commences second phase II clinical trial of IFX-1 in ANCA-associated vasculitis with first patient treated in Europe. 2019 May 14 [cited 2023 Nov 13]. Available from: https:\/\/www.inflarx.de\/Home\/Investors\/Press-Releases\/06-2019-InflaRx-Announces\u2013Top-Line-SHINE-Phase-IIb-Results-for-IFX-1-in-Hidradenitis-Suppurativa-.html"},{"key":"e_1_3_4_176_1","volume-title":"Poster session presented at: American Academy of Dermatology Annual Meeting (AAD)","author":"Alavi A","year":"2023","unstructured":"Alavi A, Prens E, Kimball A, et al. Spesolimab for hidradenitis suppurativa: proof-of-concept study. Poster session presented at: American Academy of Dermatology Annual Meeting (AAD); 2023 March 17\u201321; New Orleans, LA, USA. Poster 43019."},{"key":"e_1_3_4_177_1","doi-asserted-by":"publisher","DOI":"10.1159\/000529848"},{"key":"e_1_3_4_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.01.022"},{"key":"e_1_3_4_180_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211055920"},{"key":"e_1_3_4_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115175"},{"key":"e_1_3_4_182_1","volume-title":"Paper presented at: American Academy of Dermatology Annual Meeting (AAD)","author":"Forman S","year":"2023","unstructured":"Forman S, Patel DR, Kimball AB, et al. Safety and efficacy of LY3041658, a novel septa-specific monoclonal antibody to CXCR1 and CXCR2 ligands, in a phase 2 study in 950 hidradenitis suppurativa. Paper presented at: American Academy of Dermatology Annual Meeting (AAD); 2023 March 17\u201321, New Orleans, LA, USA."},{"key":"e_1_3_4_183_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754231154261"},{"key":"e_1_3_4_184_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15645"},{"key":"e_1_3_4_185_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16280"},{"key":"e_1_3_4_186_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15387"},{"issue":"23","key":"e_1_3_4_187_1","first-page":"00036","article-title":"Failure of dupilumab in a severe case of hidradenitis suppurativa","volume":"0151","author":"Kluger N","year":"2023","unstructured":"Kluger N. Failure of dupilumab in a severe case of hidradenitis suppurativa. Ann Dermatol Venereol. 2023;S0151\u20139638(23):00036\u20134.","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_3_4_188_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad274"},{"key":"e_1_3_4_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.047"},{"key":"e_1_3_4_190_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59040801"},{"key":"e_1_3_4_191_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.10.010"},{"key":"e_1_3_4_192_1","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omad003"},{"key":"e_1_3_4_193_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01454-2"},{"key":"e_1_3_4_194_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20969"},{"key":"e_1_3_4_195_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A study to evaluate the efficacy and safety of povorcitinib (INCB054707) in participants with moderate to severe hidradenitis suppurativa (STOP-HS1). 2023 Nov 9 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05620823"},{"key":"e_1_3_4_196_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (us). a study of oral upadacitinib tablet compared to placebo in adult participants with moderate to severe hidradenitis suppurativa to assess change in disease symptoms. 2023 Feb 23 [cited 2023 Nov 13]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04430855"},{"key":"e_1_3_4_197_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18465"},{"key":"e_1_3_4_198_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087185"},{"issue":"23","key":"e_1_3_4_199_1","first-page":"03037","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","volume":"0190","author":"Kirby JS","year":"2023","unstructured":"Kirby JS, Okun MM, Alavi A, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2023;S0190-9622(23):03037\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_4_200_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15713"},{"key":"e_1_3_4_201_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02466-4"},{"key":"e_1_3_4_202_1","volume-title":"Paper presented at: European Academy of Dermatology and Venereology","author":"Kimball A","year":"2022","unstructured":"Kimball A, Peeva E, Forman S, et al. Efficacy and safety of 3 different kinase inhibitors: brepocitinib (TYK2\/JAK1 inhibitor), IL-1 receptor associated kinase 4 (IRAK4) inhibitor, and Tyrosine kinase 2 (TYK2) inhibitor in patients with moderate to severe hidradenitis suppurativa in a Phase 2a umbrella study. Paper presented at: European Academy of Dermatology and Venereology; 2022 September 7\u201310; Milan, Spain, and virtual. (Abstract 3497)."},{"key":"e_1_3_4_203_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A study to evaluate the safety and efficacy of PF-06650833 PF-06700841 and PF 06826647 in adults with hidradenitis suppurativa. 2023 Jun 15 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/study\/nct04092452"},{"key":"e_1_3_4_204_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1570"},{"key":"e_1_3_4_205_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15677"},{"key":"e_1_3_4_206_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_3_4_207_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00767-7"},{"key":"e_1_3_4_208_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002012"},{"key":"e_1_3_4_209_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"issue":"22","key":"e_1_3_4_210_1","first-page":"01327","article-title":"Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies","volume":"0091","author":"Guttman-Yassky E","year":"2022","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol. 2022;S0091\u20136749(22):01327\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_4_211_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00499-w"},{"key":"e_1_3_4_212_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Tofacitinib for immune skin conditions in down syndrome; 2023 Jan 19 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04246372"},{"key":"e_1_3_4_213_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Study of the effect of fostamatinib upon cutaneous inflammation in the setting of hidradenitis suppurativa. 2023 Mar 3 [cited 2023 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05040698"},{"key":"e_1_3_4_214_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A single and multiple ascending dose trial of KT-474 in healthy adult volunteers and patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS). 2022 Oct 24 [cited 2023 Nov 23]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04772885"},{"key":"e_1_3_4_215_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). Orismilast for the treatment of mild to severe hidradenitis suppurativa (OSIRIS). 2021 Sep 28 [cited 2023 Nov 13]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04982432"},{"key":"e_1_3_4_216_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of medicine (US). A double-blind placebo-controlled randomized trial evaluating the efficacy and safety of a novel HSP90 inhibitor (RGRN-305) in the treatment of moderate to severe hidradenitis suppurativa; 2023 Jan 31 [cited 2023 Nov 13]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05286567"},{"key":"e_1_3_4_217_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2013.2018"},{"key":"e_1_3_4_218_1","unstructured":"ChemoCentryx [Internet]. Mountain view (CA): new releases. ChemoCentryx announces positive topline results of phase II Aurora clinical trial of avacopan in the treatment of hidradenitis suppurativa (HS). 2020 Oct 28 [cited 2023 Nov 13]. Available from: https:\/\/www.globenewswire.com\/news-release\/2020\/10\/28\/2116264\/19219\/en\/ChemoCentryx-announces-positive-topline-results-of-phase-II-AURORA-clinical-trial-of-avacopan-in-the-treatment-of-hidradenitis-suppurativa-HS.html"},{"issue":"23","key":"e_1_3_4_219_1","first-page":"01082","article-title":"A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa","volume":"0190","author":"Jepsen R","year":"2023","unstructured":"Jepsen R, Edwards C, Flora A, et al. A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa. J Am Acad Dermatol. 2023;S0190\u20139622(23):01082\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_4_220_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.113"},{"key":"e_1_3_4_221_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00954-8"},{"key":"e_1_3_4_222_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.3655"},{"key":"e_1_3_4_223_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.034"},{"key":"e_1_3_4_224_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13798"},{"key":"e_1_3_4_225_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2021.07.012"},{"key":"e_1_3_4_226_1","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0000000000000584"},{"key":"e_1_3_4_227_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad246"},{"key":"e_1_3_4_228_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad135"},{"key":"e_1_3_4_229_1","doi-asserted-by":"publisher","DOI":"10.1159\/000521263"},{"key":"e_1_3_4_230_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16766"},{"key":"e_1_3_4_231_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15507"},{"key":"e_1_3_4_232_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.52100.2"},{"key":"e_1_3_4_233_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12631"},{"key":"e_1_3_4_234_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12765"},{"key":"e_1_3_4_235_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.09.012"},{"key":"e_1_3_4_236_1","doi-asserted-by":"publisher","DOI":"10.1159\/000531496"},{"key":"e_1_3_4_237_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.4926"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2023.2298356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T15:20:38Z","timestamp":1727191238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2023.2298356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":233,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,3]]}},"alternative-id":["10.1080\/1744666X.2023.2298356"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2023.2298356","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}